Our Patented Technology Puts Treatments Within Reach of All Patients
Interested in becoming an investor?
Revolutionizing the Patient Experience
Pirouette Medical is a pharmaceutical company that leverages a deep technical skillset and industry understanding to develop and manufacture combination products that enhance the total patient experience, optimizing and broadening the applicability of the integrated drug product constituents. We pair our patented technology with generic drugs and partner with drug manufacturers to bring a significantly differentiated and competitive edge to their offerings.
Pirouette’s first opportunity is to disrupt the multi billion dollar anaphylaxis treatment market (Epinephrine) in the US. Pirouette will offer a differentiated device at an affordable price (over 75% savings). 93% of almost 1000 surveyed patients want to make the switch to Pirouette’s epinephrine auto-injector! Over 70% of 100 surveyed prescribers want to switch to prescribing our device!
A Scalable Solution for a Real Market Need
The anaphylaxis treatment market is large and growing at 8% annually in US written prescriptions.
A Clear Regulatory Pathway to Revolution
FDA approval is projected for Q3 2024. Product launch Q1 2025 with forecasted 1.4M devices sold in year 1 (8.5% penetration rate by volume, based on Auvi-Q launch which we believe is conservative).
Rapid Approach to Commercialization
We have completed design freeze and are transferring the patented design to manufacturing in phase III for design verification and validation. We have de-risked our manufacturing and testing operations through design and testing. We are using the 505(b)(2) filing pathway, there is no need for lengthy clinical trials.
Our Technology is Patented
QuicPush is protected by an IP moat throughout the US and the globe, covering the internal mechanisms, design, form factor, and future generations of the technology.
- Ease of use: 98% administration success rate.
- Simple. Controlled: 100% injection attempt rate.
- Affordable & Accessible: Over 75% reduction in price, within reach of all patients!
Existing investors
